Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this double blind study is to determine whether CERE-120 (adeno-associated
virus serotype 2 [AAV2]-neurturin [NTN]) is effective and safe in the treatment of patients
with idiopathic Parkinson's Disease. CERE-120 is administered via bilateral stereotactic
injections targeting the putaminal region of the brain. The design of this study involves
approximately 34 patients receiving CERE-120 treatment via stereotactic surgery and
approximately 17 patients receiving sham stereotactic surgery (no CERE-120 administered).